| abstract |
Compounds of formula (I) are described (see formula (I)) or its stereoisomer, tautomer or salt or solvate acceptable for pharmaceutical use, U, W, X, R1, R2, R6, R7, R30 and R31 are as described earlier in the specification; the method for inhibiting aspartyl protease is also described, and in particular, the methods for treating cardiovascular diseases, cognitive and neurodegenerative diseases; Methods for treating cognitive or neurodegenerative diseases using compounds of formula I in combination with a cholinesterase inhibitor or an m1 agonist or muscarinic m2 antagonist are also described. |